Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomethadone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 6/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 5/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esmethadone SCHEMBL24294 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL17008675 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Levomethadone SCHEMBL8506268 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL34140 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Levomethadone SCHEMBL396161 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL24293 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL7759396 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL7787108 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL18321925 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL7107052 | 0.98 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4724048-A1 | ORAL SOLID PHARMACEUTICAL FORMULATION COMPRISING METHADONE/LEVOMETHADONE AND OPTIONALLY NALOXONE | L. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETA' DI ESERCIZIO S.p.A. (IT) | 2026-04-15 | — | — | EP | claimed |
| US-20250302973-A1 | POLYMER CONJUGATES OF DRUGS WITH CENTRAL NERVOUS SYSTEM (CNS) EFFECTS AND PERIPHERAL NMDAR BLOCKING ACTIVITY AND/OR IMMUNE SYSTEM MODULATING EFFECTS | MGGM LLC | 2025-10-02 | — | — | US | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| CN-119751531-A | Preparation method of levorotatory ethyl sterenedione | 浙江仙琚制药股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4522135-A2 | POLYMER CONJUGATES OF DRUGS WITH CENTRAL NERVOUS SYSTEM (CNS) EFFECTS AND PERIPHERAL NMDAR BLOCKING ACTIVITY AND/OR IMMUNE SYSTEM MODULATING EFFECTS | University of Padova (IT) | 2025-03-19 | — | — | EP | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| US-20020176888-A1 | Oral dosage forms | GRUENENTHAL GMBH (DE) | 2002-11-28 | — | — | US | claimed |
| US-20020165248-A1 | Formulated for sustained (rapid or delayed) release of tramadol (hydrochloride); uniformity | WIMMER WALTER (DE) | 2002-11-07 | — | — | US | claimed |
| EP-1250140-A2 | COMBINATIONS OF A RECEPTOR TYROSINE KINASE INHIBITOR WITH ALPHA1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | Novartis AG (CH) | 2002-10-23 | — | — | EP | claimed |
| EP-0938316-B1 | GALENIC COMPOSITION CONTAINING OPIOID ANTAGONISTS | NORGINE EUROPE BV (NL) | 2002-07-24 | — | — | EP | claimed |
| US-6419959-B1 | ORAL ADMINISTERING; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-07-16 | — | — | US | claimed |
| US-20020044966-A1 | Pharmaceutical formulations containing an opioid and an alpha-agonist | GRUENENTHAL GMBH (DE) | 2002-04-18 | — | — | US | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| US-5989585-A | SELF-ADHESIVE LAYERED MATRIX CONTAINING ACTIVE INGREDIENT AND VITAMIN E, BACKING LINER AND RELEASE LINER | HEXAL AG (DE) | 1999-11-23 | — | — | US | claimed |
| EP-0605497-B2 | MEDICATION VEHICLES MADE OF SOLID LIPID PARTICLES (SOLID LIPID NANOSPHERES - SLN) | MEDAC KLINISCHE SPEZIALPRAEP (DE) | 1999-04-14 | — | — | EP | claimed |
| US-5858410-A | Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE (DE) | 1999-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302973-A1 | POLYMER CONJUGATES OF DRUGS WITH CENTRAL NERVOUS SYSTEM (CNS) EFFECTS AND PERIPHERAL NMDAR BLOCKING ACTIVITY AND/OR IMMUNE SYSTEM MODULATING EFFECTS | GRIN3A, GRIN1, GRIN3B | OPRM1 15/4885GRIN1 2/4885GRIN2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.